Last reviewed: June 9, 2026
Last updated: June 9, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Three GLP-1 medications currently carry FDA approval for weight loss: semaglutide, tirzepatide, and liraglutide. Clinical trials show semaglutide reduces body weight by 15–18% at maximum dose, while tirzepatide achieves 20–22% reduction. PlexusDx specializes in compounded versions of these medications alongside genetic testing that identifies your personal peptide response patterns.
FDA-Approved GLP-1 Medications for Weight Loss
The U.S. Food and Drug Administration has authorized three injectable GLP-1 receptor agonists for chronic weight management: semaglutide (marketed as Wegovy), tirzepatide (marketed as Zepbound), and liraglutide (marketed as Saxenda). Each activates the same GLP-1 receptor but differs in molecular structure, potency, and dosing schedules. Tirzepatide is technically a dual GIP/GLP-1 receptor agonist, meaning it stimulates two separate appetite-control pathways in your brain and pancreas.
Clinical evidence demonstrates semaglutide's effectiveness in the STEP trials, where participants taking 2.4 mg weekly lost an average of 18% body weight over 68 weeks. Tirzepatide's SUMO trials showed even greater reductions—up to 22.5% body weight loss at the 15 mg dose. Liraglutide, approved earlier but dosed daily rather than weekly, produces more modest results of 5–10% weight reduction. All three are administered as subcutaneous injections, though oral formulations of semaglutide and tirzepatide exist as alternatives for needle-averse patients.
How GLP-1 Medications Reduce Appetite and Body Weight
GLP-1 receptor agonists mimic glucagon-like peptide-1, a natural hormone your intestines release after eating. When this hormone binds to GLP-1 receptors in your hypothalamus (the brain region controlling hunger), it signals fullness and reduces cravings. The medications slow gastric emptying—meaning food stays in your stomach longer—which extends the sensation of satiety between meals. Additionally, these drugs may improve insulin sensitivity and reduce blood sugar spikes, which can lower overall energy intake.
Tirzepatide's dual mechanism activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP signaling further enhances energy expenditure and may promote brown adipose tissue activation, a calorie-burning fat type. This dual-pathway approach explains tirzepatide's superior weight loss outcomes in head-to-head comparisons. Individual genetic variations in GLP1R and GIPR gene expression mean some people respond more robustly to single-pathway GLP-1 therapy, while others benefit from dual activation.
Compounded vs. Brand-Name GLP-1 Medications: What's the Difference
Brand-name semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved, mass-manufactured drugs sold through conventional pharmacies with high markups. Compounded versions of semaglutide and tirzepatide are manufactured in licensed 503A compounding pharmacies under FDA oversight, using the same active pharmaceutical ingredients and rigorous quality controls. The main difference is cost: compounded medications typically cost 40–60% less because they bypass middleman markups and are not subject to brand licensing fees.
PlexusDx sources all compounded medications from licensed 503A pharmacies—never 503B (which serve hospitals and clinics). This distinction matters: 503A compounding pharmacies follow strict USP standards for sterility, potency, and purity. Your dose may need to go up over time as your body adapts, but PlexusDx pricing remains flat across all dose levels, starting at $149/month for compounded semaglutide injection. No membership, no insurance required, and HSA/FSA funds are accepted.
Genetic Testing for Personalized GLP-1 Response: The Precision Peptide Advantage
Not everyone loses the same amount of weight on the same GLP-1 medication at the same dose. Genetic variations in your GLP1R gene (rs6923761), GIPR gene (rs1800437), FTO gene (rs9939609), and MC4R gene (rs17782313) influence how sensitively your body responds to these peptide signals. Someone with a highly responsive GLP1R variant may achieve strong appetite suppression on lower doses, while a person with reduced receptor sensitivity might require higher doses or a dual-agonist approach.
PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways, 49 peptides, and 150+ genetic insights to predict your individual response profile. This test costs $99 as an add-on after your first month of treatment, allowing your PlexusDx provider to adjust your medication type or dose based on science rather than guesswork. Patients who test for GIPR sensitivity may benefit from tirzepatide's dual-pathway formula, while those with high GLP1R responsiveness may optimize results with semaglutide alone.
Managing Side Effects and Tolerability on GLP-1 Therapy
Common side effects during GLP-1 initiation include nausea, vomiting, constipation, and diarrhea—most mild and transient if your dose increases gradually. The standard protocol begins with a low dose (0.25 mg semaglutide or 2.5 mg tirzepatide weekly) and increases every 4 weeks to minimize gastrointestinal upset. PlexusDx compounded medications follow the same evidence-based titration schedules as brand-name drugs. Staying hydrated, eating smaller meals, and choosing high-protein, high-fiber foods often resolve nausea within 2–3 weeks.
Rare but serious risks include acute pancreatitis, thyroid C-cell tumors (in animal studies, not confirmed in humans), and gallbladder issues in people with a history of gallstones. Your PlexusDx provider screens for contraindications before treatment begins. If side effects become intolerable, switching between semaglutide, tirzepatide, or the Microdose GLP-1 Protocol ($129/month flat) offers lower initial doses that may suit sensitive individuals. Most patients who persist past week 4 report dramatically improved tolerance and sustained weight loss.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which GLP-1 medication is best for weight loss, semaglutide or tirzepatide?
Clinical trials show tirzepatide produces greater weight loss (up to 22% body weight) than semaglutide (15–18%), but semaglutide is often preferred first-line due to longer market history and lower cost. PlexusDx Precision Peptide Genetic Testing identifies whether your GIPR and GLP1R variants favor tirzepatide's dual-pathway approach or semaglutide's single-pathway potency, personalizing your choice.
Is compounded semaglutide as safe as brand-name Wegovy?
Yes. PlexusDx-sourced compounded semaglutide uses the same active pharmaceutical ingredient and is manufactured in licensed 503A compounding pharmacies under FDA oversight, ensuring sterility and potency identical to Wegovy. The difference is cost—compounded versions start at $149/month versus $1,300+ for brand-name.
Can I use my HSA or FSA to pay for PlexusDx GLP-1 medications?
Yes. PlexusDx compounded GLP-1 medications and the Precision Peptide Genetic Test are HSA/FSA-eligible. No insurance is required, and pricing is flat across all commitment tiers—your dose may go up, but your monthly cost stays the same.
What side effects should I expect when starting a GLP-1 medication?
Nausea, mild vomiting, constipation, and diarrhea are most common during the first 2–4 weeks, especially at dose initiation. These side effects typically resolve with gradual dose escalation and dietary adjustments (high protein, high fiber, adequate hydration). Serious adverse events like pancreatitis are rare but require immediate medical attention if severe abdominal pain develops.
How does the Precision Peptide Genetic Test improve my weight loss results?
The test identifies your genetic variants in GLP1R, GIPR, FTO, and MC4R genes across 14 metabolic pathways, predicting whether you'll respond better to semaglutide, tirzepatide, or dual-compound therapy. This science-backed personalization—costing $99 after month one—helps your PlexusDx provider optimize your medication choice and dosing strategy for maximum efficacy and minimal side effects.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
When Does Oral Semaglutide Start Working?
What is the Starting Dose of Tirzepatide for Weight Loss?